Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 18, 2025 11:00 ET | Source: NeuroSigma, Inc.

NeuroSigma Launches Next-Generation Monarch Device for Pediatric ADHD After Successful Pilot Program

LOS ANGELES, Nov. 18, 2025 (GLOBE NEWSWIRE) -- NeuroSigma, Inc., a Los Angeles-based bioelectronics company, today announced the successful completion of its pilot commercialization program for the...
June 10, 2025 09:00 ET | Source: NeuroSigma, Inc.

NeuroSigma Announces Notice of Allowance for Patent Protecting Monarch eTNS System in China

LOS ANGELES, June 10, 2025 (GLOBE NEWSWIRE) -- NeuroSigma, Inc., a Los Angeles-based bioelectronics company commercializing the Monarch external Trigeminal Nerve Stimulation (eTNS) device for...
January 22, 2025 09:00 ET | Source: NeuroSigma, Inc.

NeuroSigma Announces Patent Application Protecting Use of Trigeminal Nerve Stimulation to Include Treatment of Dyslexia and Other Neurodevelopmental Disorders

LOS ANGELES, Jan. 22, 2025 (GLOBE NEWSWIRE) -- NeuroSigma, Inc., a Los Angeles-based bioelectronics company commercializing the Monarch external Trigeminal Nerve Stimulation (eTNS) device for...
January 18, 2024 00:21 ET | Source: NeuroSigma, Inc.

NeuroSigma Announces FDA Clearance of its Second-Generation Monarch eTNS System for Treating Pediatric ADHD

LOS ANGELES, Jan. 17, 2024 (GLOBE NEWSWIRE) -- NeuroSigma today announced that the U.S. Food and Drug Administration (FDA) cleared use of NeuroSigma’s second-generation Monarch eTNS System for...
November 07, 2023 08:50 ET | Source: NeuroSigma, Inc.

NeuroSigma Announces FDA 510(k) Submission for Second Generation Monarch eTNS System

LOS ANGELES, Nov. 07, 2023 (GLOBE NEWSWIRE) -- NeuroSigma today announced it has submitted a 510(k) premarket notification to the U.S. Food and Drug Administration (FDA) for its second-generation...
October 03, 2023 09:00 ET | Source: NeuroSigma, Inc.

NeuroSigma Announces HSA Approval of the Monarch eTNS System in Singapore

LOS ANGELES, Oct. 03, 2023 (GLOBE NEWSWIRE) -- NeuroSigma today announced approval of the Monarch eTNS System by Singapore’s Health Sciences Authority (HSA), the national body that regulates medical...
September 21, 2023 06:15 ET | Source: Market Reports World

Bioelectronics Market Size 2023 is Bound To Make An Impact Business Trend, Sales Potential, Opportunities with Strategic Growth 2029

Pune, Sept. 21, 2023 (GLOBE NEWSWIRE) -- Global Bioelectronics Market [2023-2029] Research Report Analysis and Outlook Insights | Latest Updated Report | 106 Pages Report | The Bioelectronics Market...
July 12, 2023 11:00 ET | Source: NeuroSigma, Inc.

NeuroSigma Establishes Singapore Subsidiary

LOS ANGELES, July 12, 2023 (GLOBE NEWSWIRE) -- NeuroSigma, Inc. (“NeuroSigma”) today announced the launch of NeuroSigma Pte, Ltd., a Singapore corporation (“NeuroSigma Singapore”), representing...
March 01, 2023 11:00 ET | Source: NeuroSigma, Inc.

NeuroSigma Announces New Telehealth Option for Patients and Caregivers Interested in eTNS for Pediatric ADHD

LOS ANGELES, March 01, 2023 (GLOBE NEWSWIRE) -- NeuroSigma today announced a new option for patients and caregivers seeking a telehealth evaluation for the Monarch eTNS System®. NeuroSigma is a Los...
January 31, 2023 09:00 ET | Source: NeuroSigma, Inc.

NeuroSigma Announces Strategic Digital Marketing Partnership with Data360

LOS ANGELES, Jan. 31, 2023 (GLOBE NEWSWIRE) -- NeuroSigma, Inc., a Los Angeles-based bioelectronics company commercializing external trigeminal nerve stimulation (eTNS) technology for treating...